Susquehanna International Group
BBIO icon

Susquehanna International Group’s BridgeBio Pharma BBIO Stock Holding History

Susquehanna International Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.2M Buy
823,700
+272,300
+49% +$19.7M 0.01% 1138
2025
Q4 		$42.2M Sell
551,400
-197,300
-26% -$13M ﹤0.01% 1513
2025
Q3 		$38.9M Buy
748,700
+151,300
+25% +$7.38M ﹤0.01% 1542
2025
Q2 		$25.8M Buy
597,400
+92,100
+18% +$3.35M ﹤0.01% 1737
2025
Q1 		$17.5M Sell
505,300
-51,400
-9% -$1.73M ﹤0.01% 1867
2024
Q4 		$15.3M Sell
556,700
-49,900
-8% -$1.29M ﹤0.01% 2139
2024
Q3 		$15.4M Sell
606,600
-245,000
-29% -$6.43M ﹤0.01% 2093
2024
Q2 		$21.6M Buy
851,600
+326,200
+62% +$8.92M ﹤0.01% 1647
2024
Q1 		$16.2M Buy
525,400
+151,100
+40% +$5.14M ﹤0.01% 2016
2023
Q4 		$15.1M Sell
374,300
-29,000
-7% -$871K ﹤0.01% 2114
2023
Q3 		$10.6M Buy
403,300
+101,800
+34% +$2.89M ﹤0.01% 2480
2023
Q2 		$5.19M Sell
301,500
-39,400
-12% -$593K ﹤0.01% 3469
2023
Q1 		$5.65M Buy
340,900
+297,200
+680% +$3.47M ﹤0.01% 3276
2022
Q4 		$333K Buy
43,700
+8,500
+24% +$81.4K ﹤0.01% 8845
2022
Q3 		$350K Sell
35,200
-111,100
-76% -$1.15M ﹤0.01% 9395
2022
Q2 		$1.33M Buy
146,300
+41,700
+40% +$349K ﹤0.01% 5838
2022
Q1 		$1.06M Sell
104,600
-507,600
-83% -$5.21M ﹤0.01% 6956
2021
Q4 		$10.2M Buy
612,200
+529,900
+644% +$22.4M ﹤0.01% 2684
2021
Q3 		$3.86M Buy
82,300
+15,800
+24% +$847K ﹤0.01% 4426
2021
Q2 		$4.05M Sell
66,500
-21,400
-24% -$1.22M ﹤0.01% 4412
2021
Q1 		$5.42M Buy
87,900
+68,600
+355% +$4.49M ﹤0.01% 3757
2020
Q4 		$1.37M Sell
19,300
-4,900
-20% -$236K ﹤0.01% 5948
2020
Q3 		$908K Buy
24,200
+7,400
+44% +$233K ﹤0.01% 6346
2020
Q2 		$548K Sell
16,800
-43,900
-72% -$1.34M ﹤0.01% 7177
2020
Q1 		$1.76M Buy
+60,700
New +$1.88M ﹤0.01% 4195

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's BBIO Position: Q1 2026 in Review

Susquehanna International Group reduced its BridgeBio Pharma (BBIO) stake by 18% in Q1 2026, selling an estimated $6.41M and leaving 398,943 shares worth $29.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1755.

Susquehanna International Group first reported a position in BBIO in Q3 2019 and has held it in 26 quarters since. The position peaked at $37.3M in Q4 2025. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Susquehanna International Group held 398,943 shares of BridgeBio Pharma worth $29.6M as of Q1 2026.
  • Susquehanna International Group sold 88,433 BridgeBio Pharma shares in Q1 2026, an estimated $6.41M.
  • BridgeBio Pharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #1755 holding.
  • Susquehanna International Group first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 26 quarters since.
  • Susquehanna International Group's BridgeBio Pharma position peaked at $37.3M in Q4 2025.
  • 458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.